Basel positions itself as international fintech hub
The Swiss National Bank is working on a fintech project with the SIX stock exchange to explore technological options to make digital central bank money available. The study is being conducted at the new Swiss BIS Innovation Hub Center in Basel.
Headquarter of the Bank for International Settlements in Basel (img: BIS)
The Swiss National Bank (SNB) is working with SIX on a proof of concept study, announced a statement. The aim is to research how digital central bank money could be used in the settlement of tokenized assets between market participants. As the SNB explains, tokens are “digital assets that can be transferred from one party to another”.
The foundation for the new study is the SIX Digital Exchange (SDX), based on the so-called Distributed Ledger Technology (DLT). Crypto currencies such as bitcoin are based on DLT. The study is being conducted at the new Swiss BIS Innovation Hub Center in Basel, which was founded by the SNB and the Basel-headquartered Bank for International Settlements (BIS).
Following the announcement of the new center in the summer, the agreement was signed on Tuesday. According to the SNB, the Innovation Hub will serve as a center for a network of innovation experts, elevating Basel to the status of an internationally important fintech center. There are also Innovation Hubs in Hong Kong and Singapore.
Alongside the proof of concept study, a second fintech project is being conducted at the Basel BIS Innovation Hub Center. It will address the requirements placed on central banks “to monitor fast-paced electronic markets”.
“The SNB has for some time been closely following the digitalisation of the financial sector and technological innovations in the areas covered by its mandate. Through the cooperation at the BIS Innovation Hub Centre in Switzerland, the SNB will be able to further expand its expertise in the area of financial markets and their infrastructures. We look forward to bolstering our collaboration with the BIS and other central banks in this space,” commented SNB President Thomas Jordan.
Share this article
You might also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More
We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.Read More